A-HERO

Anthelmintic Research and Optimization

 Coordinatore SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Switzerland [CH]
 Totale costo 1˙927˙350 €
 EC contributo 1˙927˙350 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2013-CoG
 Funding Scheme ERC-CG
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-05-01   -   2019-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT

 Organization address address: SOCINSTRASSE 57
city: Basel
postcode: CH-4002

contact info
Titolo: Mr.
Nome: Stefan
Cognome: Mörgeli
Email: send email
Telefono: +41 61 2848320

CH (Basel) hostInstitution 1˙927˙350.00
2    SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT

 Organization address address: SOCINSTRASSE 57
city: Basel
postcode: CH-4002

contact info
Titolo: Prof.
Nome: Jennifer Irene
Cognome: Keiser
Email: send email
Telefono: +41 612848218

CH (Basel) hostInstitution 1˙927˙350.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

mansoni    anthelmintic    children    aged    chip    discovery    praziquantel    pharmacokinetic    haematobium    health    drug    infection    infected    validated    treatment   

 Obiettivo del progetto (Objective)

'I propose an ambitious, yet feasible 5-year research project that will fill an important gap in global health. Specifically, I will develop and validate novel approaches for anthelmintic drug discovery and development. My proposal pursues the following five research questions: (i) Is a chip calorimeter suitable for high-throughput screening in anthelmintic drug discovery? (ii) Is combination chemotherapy safe and more efficacious than monotherapy against strongyloidiasis and trichuriasis? (iii) What are the key pharmacokinetic parameters of praziquantel in preschool-aged children and school-aged children infected with Schistosoma mansoni and S. haematobium using a novel and validated technology based on dried blood spotting? (iv) What are the metabolic consequences and clearance of praziquantel treatment in S. mansoni-infected mice and S. mansoni- and S. haematobium-infected children? (v) Which is the ideal compartment to study pharmacokinetic parameters for intestinal nematode infections and does age, nutrition, co-infection and infection intensity influence the efficacy of anthelmintic drugs? My proposed research is of considerable public health relevance since it will ultimately result in improved treatments for soil-transmitted helminthiasis and pediatric schistosomiasis. Additionally, at the end of this project, I have generated comprehensive information on drug disposition of anthelmintics. A comprehensive database of metabolite profiles following praziquantel treatment will be available. Finally, the proof-of-concept of chip calorimetry in anthelmintic drug discovery has been established and broadly validated.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

NEUROINT (2011)

How the brain codes the past to predict the future

Read More  

KINETOCORE (2008)

Molecular Dissection of the Kinetochore – Microtubule Interface

Read More  

INDIVUHEART (2014)

Individualized early risk assessment for heart diseases

Read More